This study tests the safety and effectiveness of a new drug, R3R01, for people with certain kidney diseases: Alport Syndrome (AS) and Focal Segmental Glomerulosclerosis (FSGS). Alport Syndrome is a genetic condition affecting the kidneys, ears, and eyes, while FSGS is a disease that causes scarring in parts of the kidney. Participants must be 12 years or older and will take R3R01 for 12 weeks. The study will measure how much the drug reduces protein levels in the urine, which is a sign of kidney damage.

• The study lasts for 12 weeks, and participants will receive R3R01 throughout this period.
• Participants need to meet specific health criteria and be willing to follow study guidelines, including birth control use if applicable.
• Potential risks include possible drug side effects, but the study aims to improve kidney function by reducing protein buildup.